Source 1review1998Leukemia & lymphoma/Leukemia and lymphoma
Toolkit/Fas-blocking monoclonal antibody
Fas-blocking monoclonal antibody
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
These target T cells were protected from programmed cell death by preincubation of T cells with a Fas-blocking monoclonal antibody (mAb)...
Usefulness & Problems
Why this is useful
This monoclonal antibody is used to block Fas on target T cells before coculture. In the abstract, that intervention protects the cells from programmed cell death.; blocking Fas receptor signaling in target cells; testing whether apoptosis depends on Fas engagement
Source:
This monoclonal antibody is used to block Fas on target T cells before coculture. In the abstract, that intervention protects the cells from programmed cell death.
Source:
blocking Fas receptor signaling in target cells
Source:
testing whether apoptosis depends on Fas engagement
Problem solved
It helps test whether observed killing depends on Fas receptor engagement on the target cell side.; provides a receptor-side intervention to test causality in Fas-mediated cell death
Source:
It helps test whether observed killing depends on Fas receptor engagement on the target cell side.
Source:
provides a receptor-side intervention to test causality in Fas-mediated cell death
Problem links
provides a receptor-side intervention to test causality in Fas-mediated cell death
LiteratureIt helps test whether observed killing depends on Fas receptor engagement on the target cell side.
Source:
It helps test whether observed killing depends on Fas receptor engagement on the target cell side.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Techniques
Functional AssayTarget processes
signalingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
It requires access to a Fas-blocking antibody and a cell-based apoptosis assay involving Fas-sensitive target T cells.; requires preincubation of target T cells; use is limited to contexts where Fas-mediated signaling is under study
The abstract does not establish this antibody as a therapeutic agent or define its specificity beyond the reported blocking use.; the abstract does not specify clone, format, or broader performance characteristics
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.
Overexpression of the caspase inhibitor CrmA protected target T cells from killing by myeloma cells, supporting assignment of the killing mechanism to Fas/FasL-mediated signaling.
Approval Evidence
1 source1 linked approval claimfirst-pass slug fas-blocking-monoclonal-antibody
These target T cells were protected from programmed cell death by preincubation of T cells with a Fas-blocking monoclonal antibody (mAb)...
Source:
mechanistic interference summarysupports
Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.
Source:
Comparisons
Source-stated alternatives
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Source:
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Source-backed strengths
reported to protect target T cells from programmed cell death in the described assay
Source:
reported to protect target T cells from programmed cell death in the described assay
Compared with CrmA overexpression
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Shared frame: source-stated alternative in extracted literature
Strengths here: reported to protect target T cells from programmed cell death in the described assay.
Relative tradeoffs: the abstract does not specify clone, format, or broader performance characteristics.
Source:
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Compared with FasL-neutralizing monoclonal antibody
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Shared frame: source-stated alternative in extracted literature
Strengths here: reported to protect target T cells from programmed cell death in the described assay.
Relative tradeoffs: the abstract does not specify clone, format, or broader performance characteristics.
Source:
The abstract also describes a FasL-neutralizing monoclonal antibody and CrmA overexpression as alternative ways to interfere with the same pathway.
Ranked Citations
- 1.